OpenAI’s Whisper often hallucinates harmful content, challenging its suitability for healthcare applications where accuracy is critical to patient safety.
Pfizer raises full-year revenue guidance by $1.5B: The drugmaker’s Q3 earnings represent a near-term win, but one quarter of strong performance won’t appease its activist investor for long.
Half of insured patients can’t predict their Rx costs: It’s causing some to abandon their meds. Big Pharma must provide more resources to improve adherence rates.
Most digital hypertension tools are not cost-effective: Healthcare orgs will be less likely to invest in health tech solutions as more evidence questions their value.
Senators probe Pfizer, Eli Lilly about their D2C telehealth platforms: But we don’t expect a slowdown in Big Pharma’s push into direct-to-consumer sales. Here’s why.
Failure to secure patient data on a vast scale underscores how neglected safeguards put sensitive health information at risk.
Patients prefer AI-generated messages in their EHR: We unpack the results of new research that highlights AI’s ability to show empathy in patient communications.
Haleon debuts AI-powered screening tool for advertising: Marketers are failing to connect with diverse audiences. They’ll need to focus on AI-driven personalization to create resonant content.
Some health systems scale back telehealth offerings: But trimming virtual care too much may cause patients to flee to competing healthcare providers.
AI dominates HLTH conference: We explore the most significant AI news from the event and examine why some health systems feel a sense of urgency to invest in AI.
Novo asks FDA to ban compounders from making GLP-1 copies: The drugmaker argues Ozempic’s key ingredient is too complex to make safely, even during shortages. With patient access to affordable GLP-1s on the line, the FDA has a difficult decision to make.
Blue Shield of California, Salesforce partner to streamline the prior authorization process: But denial rates are soaring. So, things aren’t going to get materially better since insurers are often better off denying expensive treatments.
Biden-Harris administration proposes expansions to the Affordable Care Act: Its timely proposal to cover over-the-counter contraception for free is a shrewd political play to sway undecided voters.
Walmart rolls out same-day delivery for Rx, general items: The new service threatens struggling retail pharmacy chains, but we think Walmart’s main motivation is to capture customers for its membership program.
Bad actors flood the GLP-1 weight loss drug market: Until the cost of branded GLP-1s drops, illegal online pharmacies advertising falsified versions of the drugs will keep lingering.
Adults over 50 don’t trust online sources of health info: Health and pharma marketers must re-establish credibility with older patients who are skeptical of what they see online.
CVS Health replaces CEO Karen Lynch: With its insurance arm, Aetna, failing to meet investors’ expectations, CVS’ decision to appoint a longtime pharmacy benefit manager exec as CEO could be just what the doctor ordered to start turning its financial fortunes around.
Could in-store health clinics drive grocery sales? A new report seems to think so. But the broader challenges of the retail clinic business model will likely be too difficult to overcome.
How high healthcare costs affect consumer behavior: We detail what US healthcare and pharma marketers need to know to attract consumers and build trust in their brands.
Virtual mental health platforms launch AI companions: But some AI tools have a reputation for unpredictable responses.